Item 8.01. Other Events.



On September 19, 2022, BeiGene, Ltd. ("BeiGene") announced that the Committee
for Medicinal Products for Human Use of the European Medicines Agency has issued
a positive opinion recommending approval of BRUKINSA® (zanubrutinib) for the
treatment of adult patients with marginal zone lymphoma who have received at
least one prior anti-CD20-based therapy. The full text of this press release is
filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.

On September 20, 2022, BeiGene announced that England's health technology
assessment institute, the National Institute for Health and Care Excellence, has
issued a final appraisal document recommending BRUKINSA® (zanubrutinib) for the
treatment of Waldenström's Macroglobulinemia in adults who have had at least one
treatment, only if bendamustine plus rituximab is also suitable. The full text
of this press release is filed as Exhibit 99.2 to this Current Report on Form
8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.           Description

       99.1              Press release titled "BeiGene Receives Positive

CHMP Opinion for BRUNKINSA®


                         (zanubrutinib) for the Treatment of Adults with

Marginal Zone Lymphoma" issued


                         by BeiGene on September 19, 2022

       99.2              Press release titled "NICE Recommends BeiGene's

BRUKINSA® (zanubrutinib) for


                         Patients with Waldenström's Macroglobulinemia who

have at least One Treatment"


                         issued by BeiGene, Ltd. on September 20, 2022

       104               The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses